Key result
New oral anticoagulants demonstrate excellent efficacy and safety profiles, showing potential to replace vitamin K antagonists as first-line treatment for stroke prevention in atrial fibrillation.
Why the study?
Do new oral anticoagulants prevent stroke in patients with nonvalvular atrial fibrillation compared to vitamin K antagonists?
Do new oral anticoagulants prevent stroke in patients with nonvalvular atrial fibrillation compared to vitamin K antagonists?
New oral anticoagulants represent a major advance over vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
May support NOAC preference in nonvalvular AF; leaves open need for randomized confirmation before practice change.
Liew et al. (2012) conducted a review in Nonvalvular atrial fibrillation. New oral anticoagulants (dabigatran, apixaban, rivaroxaban) vs. Vitamin K antagonists was evaluated on Stroke prevention. New oral anticoagulants demonstrate excellent efficacy and safety profiles, showing potential to replace vitamin K antagonists as first-line treatment for stroke prevention in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: